Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1/2 1

Status

Unknown 4Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4UNKNOWN 2INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 17Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

pembrolizumab 163Carboplatin 146Paclitaxel 125Cyclophosphamide 94130-nm albumin-bound paclitaxel 66Capecitabine 64Gemcitabine 54Doxorubicin 50Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 41Cisplatin 39sacituzumab govitecan 34Nivolumab 34olaparib 32Epirubicin 32Specimen Handling 28Docetaxel 28eribulin 27Bevacizumab 26durvalumab 25Drug Therapy 25Biopsy 24camrelizumab 23Magnetic Resonance Spectroscopy 22toripalimab 19Radiotherapy 17spartalizumab 16Everolimus 15veliparib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × anlotinib × Clear all
NCT05582499 2026-05-28

FASCINATE-N

Fudan University

Phase 2 Recruiting
716 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Guangdong Provincial People's Hospital

Phase 2 Completed
29 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 1/2 Not yet recruiting
59 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Sichuan Provincial People's Hospital

Phase 2 Unknown
32 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
35 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
332 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡